The company has entered into licensing agreement with Sydney-based NeuClone Pty Ltd for cell-line technology. A private specialty life-science company, NeuClone will provide the exclusive proprietary cell-line technology to be developed into bio-similar drugs targeting cancer. Biologicals are drugs made in cells and bio-generics are products similar to innovative biological medicine.
With about six to eight proteins in its pipeline, Lupin is looking to develop these biological products keeping an eye on the still-evolving regulatory framework in developed markets such as the US, European Union and Japan.
Having entered the biotech space about three years ago, Lupin expects 5 to 7 per cent of its business to come from the bio-similars business, in about five years. The company expects to have its first bio-similar product in the Indian market by early next year. It has a separate research facility in Pune, with about 100 scientists, focused on biotech.
Industry estimates the global market for bio-similars or follow-on biologic drugs at about $100 billion. The Indian market for biosimilar products, such as insulin, hormones, vaccines and plasma proteins, is about Rs 2,500 crore.
crackcrackCompany Name | CMP |
---|---|
Sun Pharma Inds. | 1797.80 |
Dr. Reddys Lab | 1213.90 |
Cipla | 1486.30 |
Lupin | 2069.95 |
Zydus Lifesciences | 948.70 |
View more.. |